Effects of canagliflozin on human myocardial redox signalling: clinical implications.
Hidekazu KondoIoannis AkoumianakisIleana BadiNadia AkawiChristos P KotanidisMurray David PolkinghorneIlaria StadiottiElena SommarivaAlexios S AntonopoulosMaria C CarenaEvangelos K OikonomouElsa Mauricio ReusRana SayeedGeorge KrasopoulosVivek SrivastavaShakil FaridSurawee ChuaiphichaiCheerag ShirodariaKeith M ChannonBarabara CasadeiCharalambos AntoniadesPublished in: European heart journal (2021)
We demonstrate for the first time that canagliflozin suppresses myocardial NADPH oxidase activity and improves NOS coupling via SGLT1/AMPK/Rac1 signalling, leading to global anti-inflammatory and anti-apoptotic effects in the human myocardium. These findings reveal a novel mechanism contributing to the beneficial cardiac effects of canagliflozin.